Media News

Waterdrop Chief Actuary Hui Teng: Good Products and Services Are the Underlying Logic of High-quality Transformation for Health Insurance

BEIJING, Dec. 21, 2022 /PRNewswire/ -- At the recently held 2022 China Insurance and Aged Healthcare Forum, Hui Teng, Chief Actuary of Waterdrop Inc., was invited to give a speech titled Good Products and Services Are the Underlying Logic of High-quality Transformation for Health Insurance. He shared Waterdrop's innovative practice in the high-quality transformation of health insurance products...

CGTN: ‘New Approaches’: How China stepped up its COVID-19 treatments

BEIJING, Dec. 21, 2022 /PRNewswire/ -- China has been racing against the clock in developing COVID-19 drugs while promoting vaccination – one for saving lives and the other for providing broad protection. While the stringent COVID-19 containment measures of the past three years helped China evade deadlier variants than Omicron and prevented many deaths, the development of effective COVID-19 treatments also...

I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”

PALO ALTO, Calif., Dec. 21, 2022 /PRNewswire/ -- I Peace, Inc. (https://www.ipeace.com), has been awarded a "Special Recognition in Cell Therapy" during BioSpectrum Asia Excellence Award 2022 ceremony held in Singapore on December 2 (https://www.biospectrumasia.com/news/115/21473/biospectrum-asia-announces-editors-choice-award-winners-for-2022.html). I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced...

Medidata awarded International Innovation Award for Medidata Sensor Cloud

SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- For the third consecutive year, Medidata, a Dassault Systèmes company, was awarded the International Innovation Award. This year, the Medidata Sensor Cloud won the award under the Service and Solution category. Sensor Cloud provides cutting-edge data ingestion capabilities focused on transforming the clinical trial experience for...

QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

SHANGHAI, Dec. 21, 2022 /PRNewswire/ --  QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅰ Clinical Data of its Q-1802 program will be presented at ASCO Gastrointestinal Cancers Symposium (ASCO-GI) hold at the San Francisco and online...

PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of...

IRVINE, Calif., Dec. 21, 2022 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) clinical trial of PMB-CT01 (BAFFR-CAR T Cells) has reached...

WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

SHANGHAI, Dec. 21, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates the company's strong performance and commitment to Environmental, Social and Governance (ESG) initiatives. The Dow Jones...

Ascletis’ NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned

HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), for treatment of liver biopsy-proven non-alcoholic steatohepatitis (NASH) patients is progressing as planned. ASC41 Phase II...

PENTAX Medical U.S. launches endoscope drying solution PlasmaTYPHOONdry

The technology is a patented solution for quickly drying flexible endoscopes MONTVALE, N.J., Dec. 21, 2022 /PRNewswire/ -- PENTAX Medical America has launched a new fast endoscope drying solution - the PlasmaTYPHOONdry. Designed to improve productivity and traceability, this system further advances endoscope drying to enhance patient safety. PlasmaTYPHOONdry System In line with their Hygiene Commitment, PENTAX Medical strives to develop innovative products,...

Sirnaomics Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

First three out of five cohorts pass safety requirements, allowing the Company to dose additional cohorts to assess safety, tolerability, pharmacokinetics and anti-tumor activity HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Dec. 21, 2022 /PRNewswire/ -- Sirnaomics Ltd. (Stock Code: 2257.HK) (the "Company", together with its subsidiaries, "Sirnaomics" or the "Group"), a leading biopharmaceutical company in discovery and...